Previous 10 | Next 10 |
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...
WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith, Scienti...
Aclaris Therapeutics press release (NASDAQ:ACRS): Q4 GAAP EPS of -$0.37 misses by $0.01. Revenue of $1.5M (-5.1% Y/Y) misses by $0.3M. For further details see: Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01, revenue of $1.5M misses by $0.3M
WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 202...
Aclaris Therapeutics (NASDAQ:ACRS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.36 and the consensus Revenue Estimate is $1.8M (+13.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and ...
ABEV,ACIW,ACRS,AEP,AGIO,AHCO,ALIM,AMT,ATHM,OTCQX:AXAHY,AZUL,BABA,BLI,BUD,CARS,CBRE,CCO,CCOI,OTCPK:CDUAF,CGEN,CLDT,CMPS,CWT,CYD,DAO,DBRG,OTCPK:DDAIF,DEN,DISCA,DISH,DOCN,OTCQX:DTEGY,EDIT,ELAN,EME,EXPI,FOLD,GCI,GLNG,GNK,GNL,GTLS,HMHC,HYLN,IBP,IMUX,IONS,IRM,ISEE,KDP,KRP,OTCPK:LBLCF,LNG,LNTH,LXP,L...
WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will particip...
Aclaris Therapeutics (NASDAQ:ACRS) appointed James Loerop as chief business officer, effective Jan. 31. Loerop recently served as executive vice president, Business Development and Strategic Planning at Anika Therapeutics. Aclaris also appointed John Schindler, as Senior Direc...
Appoints James Loerop as Chief Business Officer WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced t...
WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...